Class of Cancer Drugs Shows Potential as Chronic Obstructive Pulmonary Disease Treatment Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. World Health Organization Develops Mobile App for PrEP Guidelines

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts them for a mobile device. Read more.

4. Tofacitinib Found to Repair Permeability Defects in the Gut for Patients with Ulcerative Colitis

Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation. Read more.

3. Immunotherapy Leads to Potentially Durable Response in Patients with Multiple Myeloma

Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies. Read more.

2. High Levels of Ozone, Wood Burning Linked to Chronic Obstructive Pulmonary Disease Among Smokers, Nonsmokers

Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease. Read more.

1. Class of Cancer Drugs May Have Potential as Chronic Obstructive Pulmonary Disease Treatment

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs. Read more.

Related Videos
Biosimilars | Image credit: lexiconimages -
Medical care team | Image credit: Iryna -
Pharmacist in home infusion environment | Image credit: Satjawat -
Medical science laboratory | Image credit: alphaspirit -
Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret -
Pharmacist managing inventory | Image credit: StratfordProductions -
Nursing giving infusion to senior patient | Image credit: Studio Romantic -
Cirrhosis illustration | Image credit: Rasi -
Related Content
© 2023 MJH Life Sciences

All rights reserved.